Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging Men With Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy With Pelvic Lymph Node Dissection
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Cu 64 PSMA I and T Curium Pharma (Primary)
- Indications Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms Solar-Stage
- Sponsors Curium Pharma
Most Recent Events
- 23 Apr 2024 According to Curium media release, company announced that it has successfully enrolled and scanned patients at sites across the U.S. and will be opening clinical trial sites in Europe later this year.
- 23 Apr 2024 Status changed from not yet recruiting to recruiting.
- 05 Feb 2024 New trial record